Given that the characteristic ASPSCR1-TFE3 fusion gene drives aberrant activation of signaling pathways such as MET and vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors (TKIs) targeting these pathways, including anlotinib and cabozantinib, have been applied in the management of ASPS. The gene discussed is TFE3; the disease is alveolar soft part sarcoma.